Shopping Cart
- Remove All
Your shopping cart is currently empty
Inetetamab is a humanized monoclonal antibody targeting HER2 receptor domain IV, exhibiting antitumor activity through inducing pyroptosis in lung adenocarcinoma. It is used in studies of HER2-positive metastatic breast cancer.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $289 | In Stock | |
| 5 mg | $753 | In Stock | |
| 10 mg | $1,230 | In Stock | |
| 25 mg | $1,830 | In Stock | |
| 50 mg | $2,480 | In Stock |
| Description | Inetetamab is a humanized monoclonal antibody targeting HER2 receptor domain IV, exhibiting antitumor activity through inducing pyroptosis in lung adenocarcinoma. It is used in studies of HER2-positive metastatic breast cancer. |
| In vitro | Inetetamab is a novel anti-HER2 monoclonal antibody. In combination with cisplatin, inetetamab increases ROS levels by inhibiting HER2/AKT/Nrf2 signaling, thereby triggering NLRP3/caspase-1/GSDMB mediated pyroptosis. Synergistically enhance the anti-tumor efficacy of LUAD cells. [1] |
| In vivo | Inetetamab (20 mg/kg intraperitoneally injected) showed antitumor effects in JIMT-1 xenograft mouse models. Inetetamab (20 mg/kg intraperitoneally injected) in combination with Pyrotinib or Cyclophosphamide demonstrated significant antitumor effects in JIMT-1 and NCI-N87 xenograft mouse models. [2] |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.